New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel

evelopments in the treatment of actinic keratosis: focus on ingenol mebutate gel Review (2171) Total Article Views Authors: Berman B Published Date August 2012 Volume 2012:5 Pages 111 - 122 DOI: http://dx.doi.org/10.2147/CCID.S28905 Received: 07 June 2012 Accepted: 18 July 2012 Published: 24 August 2012 Brian Berman University of Miami Miller School of Medicine, Miami, and Center for Clinical and Cosmetic Research, Aventura, FL, USA Abstract: Actinic keratosis is a common disease in older, fair-skinned people, and is a consequence of cumulative ultraviolet exposure. It is part of a disease continuum in photodamaged skin that may lead to invasive squamous cell carcinoma. Treatment options frequently used include cryosurgery and topical pharmacologic agents, which are examples of lesion-directed and field-directed strategies. Ingenol mebutate gel was recently approved by the US Food and Drug Administration for topical treatment of actinic keratosis. While the mechanism of action of ingenol mebutate is not fully understood, in vitro and in vivo studies using tumor models indicate it has multiple mechanisms. Ingenol mebutate directly induces cell death by mitochondrial swelling and loss of cell membrane integrity preferentially in transformed keratinocytes. It promotes an inflammatory response characterized by infiltration of neutrophils and other immunocompetent cells that kills remaining tumor cells. The ability of ingenol mebutate to eliminate mutant p53 patches in ultraviolet-irradiated mouse skin suggests that it may have the potential to treat chronically ultraviolet-damaged skin. In human studies, ingenol mebutate achieved high clearance of actinic keratosis on the head and body after 2–3 consecutive daily treatments when measured by complete or partial clearance of lesions. Localized inflammatory skin responses were generally mild to moderate and resolved in less than a month.